AbbVie (NYSE: ABBV) EVP reports tax-withholding share disposition

Rhea-AI Filing Summary

AbbVie Inc. executive vice president and chief commercial officer Jeffrey Ryan Stewart reported a tax-withholding disposition of 23,812 shares of common stock at $232.08 per share on February 27, 2026. After this transaction, he directly owned 83,171 shares. An additional 1,338 shares are held indirectly by his spouse in a trust, and he disclaims beneficial ownership of those securities.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stewart Jeffrey Ryan

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CHIEF COMMERCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	02/27/2026		F		23,812	D	$232.08	83,171	D
Common Stock, $0.01 par value								1,338(1)	I	By spouse in trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person disclaims beneficial ownership of all securities held by his spouse.

	/s/ T.O. Odutayo, Attorney-in-Fact for Jeffrey R. Stewart	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AbbVie (ABBV) report for Jeffrey Ryan Stewart?

AbbVie reported that EVP and chief commercial officer Jeffrey Ryan Stewart disposed of 23,812 common shares to cover tax obligations. The transaction used shares valued at $232.08 each on February 27, 2026, as part of a tax-withholding arrangement.

Was the AbbVie (ABBV) insider transaction an open-market sale?

The transaction was reported as a tax-withholding disposition, not an open-market sale. Shares were delivered to satisfy exercise price or tax liabilities, according to the transaction code F description, rather than being sold in a typical market trade.

How many AbbVie (ABBV) shares does Jeffrey Ryan Stewart own after the filing?

Following the tax-withholding disposition, Jeffrey Ryan Stewart directly owns 83,171 AbbVie common shares. The filing also notes 1,338 shares held indirectly by his spouse in a trust, for which he disclaims beneficial ownership under the reported footnote.

What price per share was used in the AbbVie (ABBV) tax-withholding disposition?

The tax-withholding disposition used a price of $232.08 per AbbVie common share. This value is applied to the 23,812 shares delivered to cover tax or exercise obligations, as reflected in the reported non-derivative transaction on February 27, 2026.

How are the spouse’s AbbVie (ABBV) shares treated in this Form 4 filing?

The filing lists 1,338 AbbVie shares held indirectly by Jeffrey Ryan Stewart’s spouse in a trust. A footnote states he disclaims beneficial ownership of all securities held by his spouse, clarifying his reported interest in those indirectly held shares.

What does transaction code F mean in the AbbVie (ABBV) insider report?

Transaction code F indicates shares were used to pay an exercise price or satisfy tax liability by delivering securities. In this case, 23,812 AbbVie shares were disposed of as a tax-withholding mechanism, rather than as a discretionary market purchase or sale.